Status:
UNKNOWN
Diagnostic Value of the Electrocardiogram in Fabry Disease
Lead Sponsor:
University Hospital, Caen
Conditions:
Fabry
Eligibility:
All Genders
18+ years
Brief Summary
Cardiac complications occur in 78% of patients with Fabry disease and are mainly characterized by a high frequency of left ventricular hypertrophy resulting from an accumulation of GL3 in cardiomyocyt...
Eligibility Criteria
Inclusion
- Patients aged \> 18 years, with genetically confirmed Fabry disease complicated by LVH.
- Patients aged \> 18 years, with sarcomeric hypertrophic cardiomyopathy.
Exclusion
- Patients aged \< 18 years. Sarcomeric hypertrophic cardiomyopathy for which Fabry disease has not been excluded by alpha-galactosidase A assay (in men) and genetic analysis (GLA gene mutation) in women.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03362645
Start Date
March 1 2018
End Date
October 1 2019
Last Update
December 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.